ProQR Therapeutics BV ( (PRQR) ) has released its Q3 earnings. Here is a breakdown of the information ProQR Therapeutics BV presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ProQR Therapeutics BV is a biotechnology company focused on developing transformative RNA therapies using its proprietary Axiomer RNA editing technology, aimed at addressing diseases with high unmet needs. In its third-quarter earnings report for 2025, ProQR announced significant progress in its lead program, AX-0810, for cholestatic diseases, receiving CTA authorization for a Phase 1 trial and expecting initial data by the end of the year. The company reported a cash position of €106.9 million, providing a financial runway into mid-2027, despite a net loss of €33.3 million for the first nine months of 2025. Key financial metrics showed increased R&D spending at €34.8 million, reflecting ProQR’s commitment to advancing its pipeline, including partnerships with Eli Lilly. Looking ahead, ProQR remains focused on executing its strategy to deliver RNA editing therapies, with anticipated updates on its broader pipeline and ongoing collaborations.